IND-enabling program and Phase 1 clinical trial for Yuma Therapeutics' novel and proprietary lead Hsp90 inhibitor, YT-83, for the treatment of Alzheimer's disease

Research Categorization
Researcher and Organization
Principal Investigator
Principal Investigator First Name
Principal Investigator Last Name
Awardee Organization
Awardee State
Contact PI Country
Project Detail
Funding Opportunity Announcement
FY Overall Cost
Funding Organization
Agency/Funding Organization
Funding Organization Country